Women 162 items
Sex differences in Lp(a) levels across the lifespan, menopause and hormone therapy, the 30-year Women's Health Study data and the venous thromboembolism signal.
Studies
- KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)
- Baseline and on-statin Lp(a) predict events in statin trials: patient-level meta-analysis (Willeit et al., Lancet 2018)
- Lp(a) and the risk of CHD, stroke and non-vascular mortality: the Emerging Risk Factors Collaboration (JAMA 2009)
- ALPACAR: zerlasiran lowers time-averaged Lp(a) by more than 80 percent over 36 weeks in ASCVD (Nissen et al., JAMA 2024)
- Inflammation, cholesterol, Lp(a) and 30-year cardiovascular outcomes in women (Ridker et al., NEJM 2024)
- Lepodisiran phase 1: a single 608 mg dose keeps Lp(a) 94 percent down at day 337 (Nissen et al., JAMA 2023)
- Muvalaplin, the first oral inhibitor of Lp(a) formation: phase 1 (Nicholls et al., JAMA 2023)
- How much Lp(a) lowering for a clinically relevant CHD reduction? The Lp(a)-GWAS-Consortium estimate (Lamina and Kronenberg, JAMA Cardiol 2019)
- Lp(a) and myocardial infarction across seven ethnic groups: INTERHEART (Paré et al., Circulation 2019)
- First-degree relatives of people with elevated Lp(a) have more MACE: Swedish registry cohort (Kindborg et al., EHJ 2026)
- Lp(a) predicts coronary events but not stroke, and evolocumab benefits at any Lp(a): VESALIUS-CV (Monguillon et al., Circulation 2026)
- Coronary artery calcium still stratifies risk in people with elevated Lp(a): a four-cohort study (Bhatia et al., JACC 2026)
- Thirty-year cardiovascular risk in healthy women by Lp(a) threshold: the Women's Health Study (Nordestgaard AT et al., JAMA Cardiol 2026)
- Lp(a) and recurrent ASCVD in 273,770 US patients: risk rises continuously to a hazard ratio of 1.45 above 300 nmol/L (MacDougall et al., EHJ 2025)
- Only 13 percent of coronary patients worldwide would meet a 150 nmol/L trial threshold: INTERASPIRE (Barkas et al., JACC 2025)
- Lp(a) drives ASCVD, MI and aortic stenosis risk independent of C-reactive protein: Copenhagen (Thomas et al., EHJ 2023)
- Lp(a) levels in a global ASCVD population: Lp(a)HERITAGE (Nissen et al., Open Heart 2022)
- APOLLO: single ascending doses of SLN360 (zerlasiran) lower Lp(a) by up to 98 percent (Nissen et al., JAMA 2022)
- High Lp(a) accelerates low-attenuation (necrotic core) plaque progression on serial CT angiography (Kaiser et al., JACC 2022)
- Elevated Lp(a) and risk of ischaemic stroke, observational and genetic (Langsted et al., JACC 2019)
- Lp(a) predicts cardiovascular disease in familial hypercholesterolaemia independent of the LDLR mutation: SAFEHEART (Alonso et al., JACC 2014)
- IL-6 modifies Lp(a)-associated coronary risk but not aortic stenosis risk: UK Biobank (JAMA Cardiol 2026)
- Lp(a) and venous thromboembolism: a signal in premenopausal women and in postmenopausal MHT users, none in men (Ezzat et al., EHJ 2026)
- Obicetrapib lowers Lp(a) by 37 percent (15 nmol/L) in high-risk patients: pooled analysis (Nicholls et al., EHJ 2026)
- Regular aspirin use and lower incidence of aortic valve calcium and severe stenosis in people with high Lp(a): MESA (Razavi et al., EHJ 2026)
- Oxidised phospholipids on apoB predict MACE after ACS and alirocumab abolishes the relation: ODYSSEY OUTCOMES (Tsimikas et al., Circulation 2025)
- LDL-C, Lp(a) and hs-CRP are independent and synergistic predictors of MACE, on and off statins: UK Biobank (Markus et al., EHJ 2025)
- One-time LDL-C, hs-CRP and Lp(a) screening predicts 20-year events in European men and women: EPIC-Norfolk (Kraaijenhof, Nurmohamed et al., EHJ 2025)
- PREVENT equations perform well but Lp(a) adds independent risk, most in borderline- and low-risk people: MESA and UK Biobank (Bhatia et al., JAMA Cardiol 2025)
- Elevated Lp(a) in 2.9 million Chinese adults and its association with multisite subclinical atherosclerosis (Man et al., JACC 2025)
- Olpasiran lowers oxidised phospholipids on apoB by about 90 percent without moving hs-CRP or IL-6: OCEAN(a)-DOSE (Rosenson et al., JAMA Cardiol 2025)
- Zerlasiran single and multiple doses in ASCVD patients: Lp(a) down 90 percent at 201 days after two doses (Nissen et al., JAMA 2024)
- Lp(a) is associated with the onset but not the progression of aortic valve calcification: the Rotterdam Study (Kaiser et al., EHJ 2022)
- Sex differences in Lp(a) levels and associated risk by age: Copenhagen (Simony et al., Atherosclerosis 2022)
- Finding very high Lp(a): the case for routine assessment (Nurmohamed et al., Eur J Prev Cardiol 2022)
- 2021 Canadian Cardiovascular Society dyslipidaemia guidelines: Lp(a) once in a lifetime (Pearson et al., Can J Cardiol 2021)
- Genetically elevated Lp(a) shortens parental lifespan and health span (Arsenault et al., JAMA Netw Open 2020)
- Lp(a): the impact of ethnicity and of environmental and medical conditions (Enkhmaa et al., J Lipid Res 2016)
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
- Elevated hs-CRP, LDL-C and Lp(a) each independently predict 30-year stroke risk in healthy women, Women's Health Study finds (Lancet Neurol 2025)
- Alirocumab cuts cardiovascular events regardless of sex, with a larger benefit at higher baseline Lp(a) in women, ODYSSEY OUTCOMES (J Clin Lipidol 2024)
- Adding Lp(a) to ApoB improves aortic-stenosis risk prediction, especially in men, UK Biobank cohort of 365,771 (Eur J Prev Cardiol 2026)
- Only 1 in 20 young ischemic stroke patients had ever been tested for Lp(a) by 2024, despite testing more than doubling since 2015, 188,305-patient US analysis finds (J Stroke Cerebrovasc Dis 2026)
- Over a quarter of 17,594 US patients with premature ASCVD have Lp(a) of 125 nmol/L or above, with Black patients showing the highest levels (J Clin Lipidol 2025)
- High Lp(a) erases the mortality benefit of high HDL-C, especially in men, cohort of 97,396 (Coron Artery Dis 2026)
- Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis
- Each 50 mg/dL rise in Lp(a) raises premature ASCVD risk by 30% in a pooled 27,756-person, multi-ethnic US cohort (Am J Prev Cardiol 2025)
- Lp(a) above 125 nmol/L predicts ischaemic stroke in men but not women, and equally across age and ethnicity, UK Biobank analysis of 353,309 finds (Am J Prev Cardiol 2025)
- Top-percentile Lp(a) more than doubles cardiovascular event risk in both sexes without prior ASCVD, but confers no extra risk in women under 60, Mass General Brigham registry finds (J Am Heart Assoc 2025)
- A Lancet review by Nordestgaard and Langsted finds one in five people carry high-risk Lp(a), as five lowering drugs achieve 65-98% reductions in trials (Lancet 2024)
- High Lp(a) triples peripheral artery disease and doubles abdominal aortic aneurysm risk, confirmed genetically, in 108,146 Danes (J Am Coll Cardiol 2023)
- Lp(a) predicts cardiovascular risk in women only when total cholesterol is high, an analysis of over 24,000 Women's Health Study participants plus WHI and JUPITER cohorts (J Am Coll Cardiol 2018)
- Lp(a) doubles coronary disease risk in men but not women, with apo(a) isoform size adding no predictive value, the Framingham Offspring Study (J Lipid Res 2011)
- An apo(a) gene variant doubles cardiovascular risk in women, but aspirin cuts that risk more than two-fold, the Women's Health Study of 25,131 participants (Atherosclerosis 2009)
- Hormone replacement therapy erases Lp(a) ability to predict cardiovascular risk in women, a study of 27,736 participants (J Am Coll Cardiol 2008)
- Only extremely high Lp(a) above the 90th percentile raises cardiovascular risk in women, the Women's Health Study of 27,791 participants (JAMA 2006)
- Lp(a) above 30 mg/dL doubles coronary disease risk in women, tripling when combined with high fibrinogen or CRP, the Nurses' Health Study of 32,826 women (Eur Heart J 2005)
- A specific LPA gene haplotype raises heart attack risk in women independent of Lp(a) level, a German study of 834 MI patients and 1548 controls (Circulation 2003)
- Lp(a) predicts heart disease risk in both sexes, with much stronger overall risk prediction in women, the ARIC study of 12,339 people (Circulation 2001)
- Estrogen plus progestin lowers Lp(a) and benefits women with high baseline Lp(a) most, the HERS trial of 2763 postmenopausal women (JAMA 2000)
- MASLD lowers Lp(a) in men and postmenopausal women but not premenopausal women, SHIP and UK Biobank cohorts (Cardiovasc Diabetol 2026)
- Genetic evidence suggests Lp(a) lowering is unlikely to raise pregnancy-complication risk, Mendelian randomisation preprint (medRxiv 2026)
- Lp(a) above 50 mg/dL raises first MI risk mainly in women with type 2 diabetes, cohort of 2,967 (Diagnostics Basel 2026)
- Lp(a) shifts across pregnancy and menopause and demands sex-specific attention, review of women's cardiovascular health (JACC Adv 2026)
- Sex Differences in Lipids and Lipoproteins and Their Relationship With Cardiovascular Disease: A Prospective Study of UK Biobank Participants
- Menopause transition triggers a fourfold larger Lp(a) rise than staying pre- or postmenopausal, UK Biobank preprint of 4,562 women (medRxiv 2026)
- Elevated Lp(a) predicts higher baseline coronary plaque burden and faster low-attenuation plaque growth on serial CT angiography (Front Cardiovasc Med 2026)
- PCSK9 inhibitors lower Lp(a) by about 17% in real-world practice, with a bigger effect at higher baseline levels and a smaller effect in women, multi-center study finds (Eur J Prev Cardiol 2025)
- Coronary calcium score adds prognostic value over Lp(a) in men but not women, MESA analysis of 4,651 participants finds (Circ Cardiovasc Imaging 2025)
- High Lp(a) drives greater fibrotic coronary plaque volume in men but not women on CT angiography, COPRODUCTION registry of 1,946 patients finds (Clin Res Cardiol 2025)
- Combined hormone therapy lowers Lp(a) by 5.1 mg/dL in postmenopausal women, meta-analysis of 27 trials finds (Diabetol Metab Syndr 2025)
- Lp(a) stays stable at the extremes, but women, statin users and those with ASCVD or high LDL-C are more likely to see borderline levels shift, 11,669-patient Mayo Clinic study finds (Eur J Prev Cardiol 2025)
- An optimal Life's Simple 7 score cuts ASCVD risk regardless of Lp(a) level, MESA cohort of 6,676 finds, but elevated Lp(a) still carries higher absolute risk at every lifestyle score (Eur J Prev Cardiol 2025)
- High Lp(a) predicts carotid atherosclerosis but not all-cause mortality over nearly three decades of follow-up, Toulouse cohort of 11,990 finds (Am J Prev Cardiol 2025)
- Higher Lp(a) predicts worse long-term outcomes after heart attack, especially in women and patients with diabetes or hypertension, meta-analysis of 30,027 patients finds (Rev Cardiovasc Med 2025)
- One in four Russians has Lp(a) above 30 mg/dL, and levels run higher in women, 73,763-patient national cohort finds (Kardiologiia 2025)
- Lp(a)HERITAGE US subanalysis finds only 14% of 7,679 ASCVD patients had ever been tested, despite median Lp(a) 2.5-fold higher in Black participants (J Clin Lipidol 2025)
- PROMISE trial analysis of 1,815 patients finds elevated Lp(a) predicts obstructive coronary disease regardless of LDL-C control, but not high-risk plaque (Am J Cardiol 2024)
- Review by Koschinsky, Rosenson and colleagues explains why Lp(a) runs up to threefold higher across racial groups and 5-10% higher in women (J Am Heart Assoc 2024)
- Only 0.25% of 2.4 million patients in a US healthcare network have ever had Lp(a) measured, with striking demographic testing gaps (J Clin Lipidol 2023)
- Menopause raises Lp(a) by 3.77 mg/dL, though ageing itself cannot be ruled out as the driver, a meta-analysis spanning 12,960 women (Maturitas 2023)
- Lp(a) is linked to more vulnerable carotid plaque features, with sex-specific patterns, in the Dutch PARISK study of 182 patients (Atherosclerosis 2021)
- Tibolone lowers Lp(a) by up to 29% depending on dose, a meta-analysis of 12 trials and 1009 postmenopausal women (Atherosclerosis 2015)
- Lp(a) predicts intermittent claudication more strongly in women than men, the Edinburgh Artery Study of 1592 adults (Atherosclerosis 2001)
- Elevated Lp(a) unexpectedly raises coronary risk in older women just as strongly as in younger men, a cohort of 918 CAD and 829 non-CAD patients (Atherosclerosis 2000)
- Lp(a) and homocysteine together raise coronary risk nearly 5-fold in women, but not men, a study of 750 men and 403 women (Arterioscler Thromb Vasc Biol 2000)
- Berberine lowers Lp(a) and apoB more in women than men, two randomised placebo-controlled trials (JACC Asia 2026)
- Lp(a) tracks non-calcified plaque in men but calcified plaque in women, 7201-person asymptomatic CCTA cohort (J Cardiol 2026)
- High Lp(a) raises AMI risk most in older women, case-control study of 2,946 patients (J Int Med Res 2026)
- Women have higher Lp(a) than men in acute coronary syndrome, Portuguese cohort of 388 (Rev Port Cardiol 2026)
- Lp(a) contributes 15% of circulating apoB in Asian healthcare workers with very high Lp(a), cohort of 1,927 (Lipids Health Dis 2026)
- Lp(a) predicts recurrent ACS despite negative fractional flow reserve testing, Chinese cohort of 513 (Rev Cardiovasc Med 2026)
- Association of Coronary Microvascular Dysfunction with Lipoprotein (a) levels in Patients with Non-Obstructive Coronary Artery Disease
- Low early-pregnancy Lp(a) independently predicts gestational diabetes in a 14,527-woman cohort (Front Endocrinol (Lausanne) 2026)
- Lp(a) rises after 50 in women and 60 in men, Polish reference study of 1,046 adults and 276 children (Biochem Med Zagreb 2026)
- Serum Lp(a) rises with disease severity and correlates with bile acid levels in intrahepatic cholestasis of pregnancy, 156-patient study finds (J Obstet Gynaecol Res 2025)
- First-trimester Lp(a) elevation raises preeclampsia risk more than fourfold, 150-woman prospective cohort finds (J Clin Med 2025)
- A 'panvascular disease' framework unifies Lp(a)'s role across coronary, cerebral, peripheral and valvular atherosclerosis, review argues, with sex-specific risk patterns (Lipids Health Dis 2025)
- Serum Lp(a) is higher in rheumatic heart valve disease and tracks with mitral stenosis severity and valve involvement, 80-patient study finds a possible new link (Lipids 2025)
- Tamoxifen lowers Lp(a) by 3.35 mg/dL, with the effect nearly 40% stronger at doses of 20 mg/day or above, updated meta-analysis of RCTs finds (Endocrine 2025)
- First large-scale Brazilian data: median Lp(a) is 13.90 mg/dL in women versus 11.58 mg/dL in men across 115,197 subjects (PLoS One 2025)
- Meta-analysis of forty-one studies finds Lp(a) nearly 12 mg/dL higher in pre-eclampsia, but not in gestational diabetes (Prog Cardiovasc Dis 2025)
- Lp(a) above 90 mg/dL predicts recurrent heart attack almost fourfold in women over 65, but shows no overall mortality link (Diagnostics 2025)
- Meta-analysis of 11 trials finds medroxyprogesterone acetate raises Lp(a) while lowering ApoA-I in postmenopausal women (Prostaglandins Other Lipid Mediat 2025)
- Review traces how Lp(a) shifts from newborn to menopause and argues women carry equal or greater Lp(a)-related cardiovascular risk than men (Am J Prev Cardiol 2024)
- At Mayo Clinic, only 0.15% of 257,225 patients with a lipid panel had Lp(a) tested within a year, and results rarely changed treatment (Am J Prev Cardiol 2024)
- STAR-Lp(a) study finds 21.5% of 2,475 outpatient cardiology patients had elevated Lp(a), more often women and those with atrial fibrillation (Pol Arch Intern Med 2024)
- Lp(a) at or above 30 mg/dL predicts coronary disease in women but not men, while 50 mg/dL works for both, in 1,858 Turkish patients (Clin Cardiol 2024)
- Meta-analysis of 12 trials finds raloxifene lowers Lp(a) and ApoB while raising ApoA-I in postmenopausal women (Clin Ther 2024)
- Quantifying LPA KIV-2 repeat number by qPCR better predicts 5-year MACE than measured Lp(a) alone, particularly in women (Rev Cardiovasc Med 2024)
- One in three stable lipid-clinic patients showed Lp(a) swings over 25%, challenging the once-in-a-lifetime testing dogma (Med Clin (Barc) 2024)
- Girls with genetic FH have 45% higher baseline Lp(a) than boys, a sex gap that persists over nearly nine years of follow-up (Atheroscler Plus 2024)
- High neutrophil-to-lymphocyte ratio unmasks Lp(a)'s prognostic harm after PCI, especially in women, 7,922-patient study finds (Angiology 2025)
- Tibolone lowers lipoprotein(a) by 7.49 mg/dL in postmenopausal women, a meta-analysis of 13 randomised trial arms (Eur J Obstet Gynecol Reprod Biol 2024)
- Women with polycystic ovary syndrome have higher Lp(a) than controls regardless of weight, a meta-analysis of 2,337 patients across 23 studies (High Blood Press Cardiovasc Prev 2023)
- Transgenic mice expressing human Lp(a) develop larger, more vulnerable, more calcified atherosclerotic plaques, an effect specific to females (Atherosclerosis 2023)
- Lp(a) is higher in Black populations and in women, but a lack of standardised assays and cutoffs still limits clinical use, a review (Best Pract Res Clin Endocrinol Metab 2023)
- Elevated Lp(a) most robustly predicts coronary events in postmenopausal women, though results are mixed for other outcomes, a systematic review of 157,690 women (Curr Probl Cardiol 2023)
- Lp(a) testing rose steadily but remained rare at the University of Rochester Medical Center, identifying only 2,698 patients ever tested (J Clin Lipidol 2023)
- Lp(a) is 50% lower in patients with fatty liver inflammation (NASH) than simple fatty liver (NAFL), a discordant biopsy-based finding in 151 patients (J Clin Lipidol 2023)
- High Lp(a) brings cardiovascular events about 7 years earlier than high LDL alone in polygenic hypercholesterolaemia, with sex-specific patterns, in 548 patients (Front Cardiovasc Med 2023)
- Anti-oestrogen therapy lowers Lp(a) by 5.92% in postmenopausal women, a meta-analysis of 10 double-blind placebo-controlled trials (Endocrine 2023)
- Hormone therapy with 17beta-estradiol plus norethisterone lowers Lp(a) by 67.6 mg/L in postmenopausal women, a meta-analysis of RCTs (Exp Gerontol 2023)
- Adding orlistat to ethinyl-estradiol/drospirenone lowers Lp(a) in overweight PCOS patients, the first study of this combination, an RCT of 66 patients (Gynecol Endocrinol 2022)
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
- Lp(a) is not linked to bone density or hip fracture risk in 9698 postmenopausal women, a Women's Health Initiative post hoc analysis (BMJ Open 2019)
- Raloxifene lowers Lp(a), with the effect fading over longer treatment duration, a meta-analysis of 7 trials in postmenopausal women (Cardiovasc Drugs Ther 2017)
- Oral hormone replacement therapy lowers Lp(a) by about 20%, but tibolone does not, a meta-analysis of 24 studies in postmenopausal women (Maturitas 2017)
- Lp(a) ranges from under 0.1 to over 100 mg/mL between individuals, and is higher in women, a review of its evolutionary origins and genetic determinants (Curr Med Chem 2017)
- Hormone therapy cuts Lp(a) by up to 44% in postmenopausal women, more than niacin or PCSK9 inhibitors, a review of Lp(a) treatment options (Int J Clin Pract 2016)
- Omega-3 plus vitamin E supplementation lowers Lp(a) gene expression in women with polycystic ovary syndrome, a randomised trial of 68 patients (Mol Cell Endocrinol 2017)
- Lp(a) correlates with coronary disease severity only in men, not women, a study of 351 patients with established coronary atherosclerosis (Eur J Prev Cardiol 2015)
- 84% of high-Lp(a) patients in a lipid clinic were not on niacin despite meeting treatment criteria, a cohort of 692 patients (J Clin Lipidol 2012)
- Lp(a) impairs blood vessel dilation in healthy postmenopausal women, a Dutch study of 105 women (Atherosclerosis 2000)
- Lp(a) does not predict ischemic stroke in young women, a case-control study of 110 cases and 216 controls (Atherosclerosis 2000)
- Oral estrogen lowers Lp(a) by 23%, linked to a doubling of IGFBP-1, a trial of 73 postmenopausal women (Atherosclerosis 2000)
- Lp(a) doubles during normal pregnancy but is not further raised by pre-eclampsia, a Scottish study of 30 women (Atherosclerosis 2000)
- Lp(a) does not correlate with coronary calcium in asymptomatic postmenopausal women, a study of 178 women (J Am Coll Cardiol 2000)
- First-trimester Lp(a) predicts preeclampsia, 119-woman pilot cohort (Arch Gynecol Obstet 2026)
- From Phenotype to Genotype and Beyond: Insights into Familial Hypercholesterolemia and Familial Hypertriglyceridemia
- Improved diagnosis of familial hypercholesterolemia by correcting LDL-C for lipoprotein(a) in a German cohort
- Lp(a) does not predict long-term cardiometabolic risk in healthy women despite its lipid links, 387-woman cohort (Metabolites 2026)
- Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts
- Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis
- In severe aortic stenosis, Lp(a) does not track with valve calcium and shows only a modest, male-specific link to fibrosis, CT and cytokine study finds (J Transl Med 2025)
- Higher Lp(a) is linked to worse five-year recurrence-free prognosis in 296 endometrial cancer patients (Clin Lab 2025)
- A 44-year-old woman with low calculated ASCVD risk but severe, calcified coronary disease illustrates why Lp(a) testing shouldn't wait for guideline mandates, case-based review argues (Am Heart J Plus 2025)
- Meta-analysis of RCTs finds tamoxifen modestly lowers Lp(a) alongside ApoB in women treated for breast cancer (Exp Gerontol 2024)
- In 1,193 Turkish ASCVD patients, women were eight times more likely than men to have Lp(a) above 90 mg/dL (Turk Kardiyol Dern Ars 2024)
- Patients with elevated Lp(a) (>125 nmol/L) face very high cardiovascular risk, with early events in 65% of women and 56% of men, in 316 Spanish patients (Clin Investig Arterioscler 2024)
- Chemotherapy may raise Lp(a) in breast cancer survivors, adding cardiovascular risk on top of cancer treatment, a review (Lipids Health Dis 2023)
- Oral hormone therapy lowers Lp(a) more than transdermal, and kidney disease raises it while liver disease lowers it, a review of non-genetic influences (Atherosclerosis 2022)
- Lp(a) is higher in familial hypercholesterolaemia patients who develop early heart disease than those who don't, a Norwegian comparison study (Atherosclerosis 2011)
- Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure
- Lp(a) tracks with coronary disease in women but not men in a 220-patient hypercholesterolaemia cohort (Atheroscler Plus 2026)
- High Lp(a) drives premature, progressive coronary disease in a young woman despite optimal LDL-C control, case report (JACC Case Rep 2026)
- In 67 statin-naive adults, Lp(a) is independent of the standard lipid profile but rises with age, reinforcing the case for dedicated screening (Wiad Lek 2025)
- Case report: Lp(a) of 113 mg/dL behind recurrent deep vein thrombosis and cerebral venous sinus thrombosis across two pregnancies (Case Rep Neurol 2025)
- A bibliometric map of Lp(a) research finds inflammation, aortic valve stenosis and postmenopausal hormone changes as the dominant themes (Front Public Health 2022)
- Two women with normal cholesterol and low coronary calcium scores still had significant coronary disease and high Lp(a), a case report (J Clin Lipidol 2020)
- Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study
- Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations